Wolverine Stack: What BPC-157 + TB-500 Research Shows

Search the phrase "wolverine stack" and almost every result is a storefront. The name is attached to two research compounds, BPC-157 and TB-500, bundled together and sold for recovery, and it borrows its promise from a comic-book character whose entire gimmick is that injuries stop mattering. What the shop pages skip is how the research is distributed. Each compound has its own small, mostly animal-based file. The pairing being sold has none. This guide grades the two halves separately, because that is what the evidence allows.

What the name is attached to

"Wolverine stack" is a marketing label, not a scientific one. There is no standardized formula behind it, and vendors apply the label to BPC-157 and TB-500 offered as a bundle, sometimes with other compounds folded in. Both are peptides. BPC-157 is a synthetic fifteen-amino-acid sequence derived from a protein found in gastric juice. TB-500 is sold as a relative of thymosin beta-4, a protein involved in cell movement and tissue remodelling. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons groups the two under wound-healing peptides and describes them as acting on angiogenesis, extracellular-matrix remodelling and fibroblast activation. The same review states the evidence position plainly: although preclinical studies are promising, there is a current lack of clinical trials.^[1]

TB-500 is not the protein it is named after

One detail disappears in the marketing, and it changes how every TB-500 claim should be read. Analytical work published in Drug Testing and Analysis in 2012 examined material sold as TB-500 and identified it not as thymosin beta-4 but as a short piece of it, the N-terminally acetylated 17-23 fragment, Ac-LKKTETQ. That distinction matters because much of the research people cite for TB-500 was carried out on full-length thymosin beta-4, which is a different molecule. When a product listing points at thymosin beta-4 studies to support a TB-500 purchase, two separate substances are being presented as one.^[2]

Grading half one: BPC-157

BPC-157's published record is dominated by rodent work. A 2025 literature and patent review in Pharmaceuticals concludes that it has not been approved for use in standard medicine by the FDA and other global regulatory authorities, citing the absence of sufficient and comprehensive clinical studies confirming its benefits in humans. Its published safety package is animal toxicology, carried out in mice, rats, rabbits and dogs. A 2026 primer in the American Journal of Sports Medicine describes the tendon and muscle findings as largely unvalidated in human trials, and notes that the one human case series carries significant methodological flaws and a lack of controls. A Phase 2 study in acute grade II hamstring strain opened in the public trial registry in 2026, the first entry designed to ask whether the compound changes an injury outcome in people.^{[3, 4, 5, 6]}

Grading half two: TB-500

The human file for TB-500 is thinner still. The same 2026 sports-medicine primer reports that its evidence comes from preclinical work, that human orthopaedic data are lacking, and that it is listed among substances banned in sport. Full-length thymosin beta-4 has been studied in people across several indications, and a 2021 review in Frontiers in Endocrinology lists myocardial infarction, dry eye and skin trauma among them. Per the identification work above, though, that is a different molecule from the fragment sold as TB-500, so those studies do not transfer. Reviewing the fragment as a candidate substance for pharmacy compounding, the FDA has not identified any human exposure data for products containing it.^{[5, 7, 2, 8]}

The combination itself has never been studied

No published study, in people or in animals, has examined BPC-157 and TB-500 as a pair. A search of the public trial registry for the two compounds together returns nothing. Three separate 2026 reviews cover both compounds, from orthopaedic, sports-medicine and musculoskeletal angles, and each one discusses the two substances individually without reporting or citing a combination experiment. Reviews in this field do describe tested pairings when they exist. The same orthopaedic review discusses ipamorelin together with CJC-1295 as a combination with a reported joint effect. Nothing equivalent has been published for this pairing. The stack is a commercial arrangement rather than a studied one.^{[1, 5, 9]}

What "synergy" is doing in the sales copy

Synergy carries most of the weight on a stack page, so the word deserves a precise reading. The argument runs like this: BPC-157's research centres on angiogenesis and matrix remodelling, TB-500's centres on cell migration and cytoskeletal work, and therefore the two should complement each other. As a hypothesis, that is reasonable. As a finding, it does not exist. Synergy is a measurable claim, meaning a combined effect greater than the sum of the parts, and measuring it requires an experiment that tests the pair against each compound alone. No such experiment has been published for these two. Until one is, synergy on a Wolverine stack page describes an expectation rather than a result.^[1]

Where regulators actually stand

Both compounds appear on the FDA's list of bulk drug substances that may present significant safety risks, in the section covering substances nominated for pharmacy compounding and later withdrawn by their nominators. The agency's note on BPC-157 records no, or only limited, safety information for the proposed routes. Its note on the thymosin beta-4 fragment says no human exposure data was found for products containing it. In both cases the agency states it lacks the information it would need to judge whether the substance would cause harm in people. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee examined both again, weighing BPC-157 and TB-500 for inclusion on the 503A bulks list, with BPC-157 examined for ulcerative colitis and TB-500 for wound healing. Neither of those uses is the sports-injury use the stack is marketed for, and the two were weighed as separate substances rather than as a blend.^{[8, 10]}

Banned in sport, under two separate sections

For anyone competing under anti-doping rules, both compounds are prohibited, and the Prohibited List says so without ambiguity. The 2026 WADA Prohibited List, valid from 1 January 2026, names BPC-157 outright in section S0, the non-approved-substances class covering any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use. Section S2.3, growth factors and growth factor modulators, lists thymosin-beta4 and its derivatives and gives TB-500 as its example. Both sections are prohibited at all times, in and out of competition, so neither compound has an off-season window. The secondary literature has been less consistent than the List itself: a 2023 doping-control paper in Molecules records BPC-157's addition under S0 in 2022, while a 2025 review describes it as no longer listed. The List settles that, because the List is the governing document and the 2026 edition names the compound. A 2025 equine doping-control study and the 2026 sports-medicine primer agree with it on the thymosin beta-4 side. The practical step is to read the current List for your own sport rather than any paper's summary of it, this one included.^{[14, 11, 3, 12, 5]}

The supply problem underneath both halves

Every claim above assumes the vial holds what the label says. That assumption has been tested, and the result was not reassuring. A peptide-purity study in Analytical Biochemistry examined the same research peptide bought from five manufacturers. One product turned out to be an entirely different peptide, and two-thirds of the remainder fell below the purity a laboratory experiment would require, coming in under 95% pure or carrying individual impurities above 1%. That study looked at a different compound, so it is not a measurement of BPC-157 or TB-500 supply specifically. It is a measurement of how reliable the unregulated research-peptide channel proved when somebody checked. The 2026 sports-medicine review makes a similar point about the wider market, describing a gray market of unapproved compounds operating largely outside of regulatory oversight.^{[13, 9]}

How to read any marketed blend

The method that survives contact with a stack page is the one used above. Grade each component on its own evidence, then ask separately what has been shown about the combination. The second answer is usually nothing, and that absence is the most useful thing on the page. The general version of this reasoning is in our explainer at /learn/what-is-a-peptide-stack. The component-by-component grades for this particular pairing, with a verdict attached to each half, are on the data sheet at /peptides/wolverine-stack. If what you want instead is a head-to-head, comparing which compound has the better-supported research file and on which endpoints, that comparison is at /compare/bpc-157-vs-tb-500. This page decodes the blend; that one weighs the parts against each other.

References & sources

1. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID 41490200.
2. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PMID 22962027.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025. PMID 40005999.
4. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020. PMID 32334036.
5. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PMID 41476424.
6. ClinicalTrials.gov NCT07437547. A randomized, double-blind, placebo-controlled Phase 2 trial of pentadecapeptide BPC 157 in acute grade II hamstring strain confirmed by MRI. Recruiting; study start February 2026.
7. Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin beta-4. Front Endocrinol (Lausanne). 2021. PMID 34992578.
8. U.S. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks - the "bulk drug substances nominated but withdrawn" list, which carries entries for BPC-157 and for "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500".
9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID 41966639.
10. U.S. FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - agenda listing BPC-157-related and TB-500-related bulk drug substances considered for inclusion on the 503A Bulks List, with the uses examined for each.
11. Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules. 2023. PMID 37959764.
12. Delcourt V, Garcia P, Chabot B, et al. Equine Doping Controls of Thymosin beta-4: A Population Study and Strategy for Misuse Detection. Drug Test Anal. 2025. PMID 39314109.
13. De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. Anal Biochem. 2008. PMID 18342612.
14. World Anti-Doping Agency. 2026 Prohibited List, valid 1 January 2026. Section S0 (Non-Approved Substances) names BPC-157; section S2.3 (Growth Factors and Growth Factor Modulators) lists Thymosin-beta4 and its derivatives, e.g. TB-500.